Author

Robert J. Van Gulick

Observed names: R. Van Gulick, Rob Van Gulick, Robert J Van Gulick, Robert Van Gulick

Institution: Cogent Biosciences (United States)

Observed institutions: University of Colorado Cancer Center, Cogent Biosciences (United States), University of Colorado Anschutz, University of Colorado Denver

ORCID: 0000-0002-6300-9569

Observed ORCID: 0000-0002-6300-9569

OpenAlex ID: A5062356933

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

2020 · Felicity Newell, James S. Wilmott, et al. · Nature Communications · 187

PDF

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

2022 · Richard P. Tobin, Dasha T. Cogswell, et al. · Clinical Cancer Research · 106

PDF

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

2020 · Nabanita Mukherjee, Jenette Skees, et al. · Cell Death and Disease · 80

PDF

Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity

2023 · Jacqueline A. Turner, Malia A. Fredrickson, et al. · Nature Communications · 61

PDF

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma

2022 · Halis Kaan Akturk, Kasey L. Couts, et al. · JAMA Network Open · 42

PDF

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

2018 · Jacqueline A. Turner, Judson G. T. Bemis, et al. · Oncogene · 42

Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas

2020 · Blair N. Holman, Robert J. Van Gulick, et al. · Melanoma Research · 39

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

2020 · Nabanita Mukherjee, Carol M. Amato, et al. · Cancers · 35

PDF

Circulating CD8 + mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients

2022 · Victoria M Vorwald, Dana M Davis, et al. · Clinical & Translational Immunology · 34

BRAF Modulates Lipid Use and Accumulation

2022 · Jacqueline A. Turner, Emily L. Paton, et al. · Cancers · 23

PDF

Biomarkers to predict immune-related adverse events with checkpoint inhibitors.

2019 · Lia Head, Nicholas Gorden, et al. · Journal of Clinical Oncology · 20

Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors

2021 · Jessica S.W. Borgers, Richard P. Tobin, et al. · Journal of the National Comprehensive Cancer Network · 15

PDF

Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling

2024 · Jacqueline A. Turner, Robert J. Van Gulick, et al. · International Journal of Cancer · 11

PDF

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

2021 · Chiara R. Dart, Nabanita Mukherjee, et al. · Pharmaceuticals · 5

PDF

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.

2021 · Martin McCarter, Richard P. Tobin, et al. · Journal of Clinical Oncology · 5

Targeting the RIG-I-like receptor signaling pathway to improve the efficacy of immunotherapy in mucosal and uveal melanoma.

2021 · Morgan L. MacBeth, Robert J. Van Gulick, et al. · Journal of Clinical Oncology · 2

Abstract PO048: Loss of intra-tumoral RIG-I immune signaling is a potential microbiome-mediated mechanism underlying poor anti-tumor immunity and immunotherapy resistance in mucosal melanoma

2021 · Morgan MacBeth, Richard Tobin, et al. · Cancer Research · 2

Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor

2025 · Aaron C. Smith, Ben Arwood-Levine, et al. · Cancer Research · 1

Supplementary table 4 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma